Patents by Inventor Kirk W. Johnson

Kirk W. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090028816
    Abstract: The use of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) for treating affective disorders, such as depression, psychosis, or anxiety, is described.
    Type: Application
    Filed: July 22, 2008
    Publication date: January 29, 2009
    Inventors: Lance Sultzbaugh, Kirk W. Johnson
  • Publication number: 20080287402
    Abstract: The use of a glial attenuator, such as ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), to prevent the negative consequences of glial priming is described. In particular, the present invention is directed to a method of treating a subject with ibudilast to prevent amplified pain responses to inflammation or injury as a result of glial priming following an initial glial activating event.
    Type: Application
    Filed: May 1, 2008
    Publication date: November 20, 2008
    Inventors: Kirk W. Johnson, Linda R. Watkins
  • Publication number: 20080181876
    Abstract: Methods of potentiating opioid-induced analgesia in a subject by administration of a phosphodiesterase (PDE) inhibitor or glial attenuator are described. In particular, the present invention is directed to methods of treating or preventing acute or subchronic pain by administration of a PDE inhibitor or glial attenuator, such as ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), in combination with an opioid.
    Type: Application
    Filed: January 29, 2008
    Publication date: July 31, 2008
    Inventors: Kirk W. Johnson, Linda R. Watkins, Mark Hutchinson
  • Patent number: 7383158
    Abstract: A system for servicing a computer controlled machine comprising: a computer controlled machine including a device operable to perform a function, a controller controlling the operation of that device, and a data access port for transferring data and commands from the controller; and a service tool operably connected to the data access port, the service tool including a remote communications capability, a computer, and diagnostics and graphing software; and an expert observer system operably linked to the remote communications capability of the service tool and including historical machine data, machine sales information, software revisions for the controller, additional diagnostics software, and an expert observer capable of providing a mentor capability to the operator of a service tool.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: June 3, 2008
    Assignee: Trane International Inc.
    Inventors: Robert E. Krocker, Terence D. Baier, Merle A. Renaud, Paul C. Rentmeester, Robert M. Swanson, Patrick J. Wilson, Kirk W. Johnson
  • Publication number: 20080107678
    Abstract: Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.
    Type: Application
    Filed: April 24, 2007
    Publication date: May 8, 2008
    Inventor: Kirk W. Johnson
  • Patent number: 7037918
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: May 2, 2006
    Assignee: Chiron Corporation
    Inventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Sean P. Brown, Dane A. Goff, Kirk W. Johnson, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Lynn Seely, Sharadha Subramanian, Allan S. Wagman, Xiaohui A. Zhou
  • Publication number: 20030195640
    Abstract: A system for servicing a computer controlled machine comprising: a computer controlled machine including a device operable to perform a function, a controller controlling the operation of that device, and a data access port for transferring data and commands from the controller; and a service tool operably connected to the data access port, the service tool including a remote communications capability, a computer, and diagnostics and graphing software; and an expert observer system operably linked to the remote communications capability of the service tool and including historical machine data, machine sales information, software revisions for the controller, additional diagnostics software, and an expert observer capable of providing a mentor capability to the operator of a service tool.
    Type: Application
    Filed: April 16, 2002
    Publication date: October 16, 2003
    Inventors: Robert E. Krocker, Terence D. Baier, Merle A. Renaud, Paul C. Rentmeester, Robert M. Swanson, Patrick J. Wilson, Kirk W. Johnson
  • Publication number: 20030130289
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Application
    Filed: December 3, 2002
    Publication date: July 10, 2003
    Applicant: Chiron Corporation
    Inventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Sean P. Brown, Dane A. Goff, Kirk W. Johnson, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Lynn Seely, Sharadha Subramanian, Allan S. Wagman, Xiaohui A. Zhou
  • Patent number: 6489344
    Abstract: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: December 3, 2002
    Assignee: Chiron Corporation
    Inventors: John M. Nuss, Stephen D. Harrison, David B. Ring, Rustum S. Boyce, Sean P. Brown, Dane A. Goff, Kirk W. Johnson, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Lynn Seely, Sharadha Subramanian, Allan S. Wagman, Xiaohui A. Zhou
  • Patent number: 5998622
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I; ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: December 7, 1999
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Patent number: 5919936
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Patent number: 5817671
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A--B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Patent number: 5744482
    Abstract: Methods for the treatment or prevention of migraines comprising administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and a serotonin agonist are disclosed. The administration may be concurrent or sequential, with either of the two activities being administered first.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: April 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, Kirk W. Johnson, Lee A. Phebus
  • Patent number: 5698571
    Abstract: The present invention provides a method for the treatment of migraine with compounds or compositions that are selective agonists of 5-HT.sub.1F receptors relative to other serotonin receptors that produce unwanted effects like vasoconstriction. The neurogenic meningeal extravasation that leads to the pain of migraine is inhibited.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: December 16, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Marlene L. Cohen, Kirk W. Johnson, Lee A. Phebus, Theresa Branchek
  • Patent number: 5411647
    Abstract: A method of improving the utility of electrochemical glucose sensors by decreasing either or both their settling time and their sensitivity to interfering compounds. In particular, the settling time of an electrochemical glucose sensor is improved by pretreating the operating electrode with a negative electric current at a constant current density. The sensor's sensitivity to intefering compounds is reduced by operating the sensor at a reduced voltage while the glucose concentration measurement is being made.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: May 2, 1995
    Assignee: Eli Lilly and Company
    Inventors: Kirk W. Johnson, John J. Mastrototaro
  • Patent number: 5322063
    Abstract: Homogeneous membranes permeable to oxygen and glucose composed of hydrophilic polyurethanes that are capable of absorbing from 10 to 50% of their dry weight of water. Variations in the composition of the hydrophilic polyurethanes make possible the fabrication of membranes in which the ratios of the diffusion coefficients of oxygen to glucose can be varied over a wide range. These membranes can be used in the fabrication of an electrochemical glucose sensor intended for use in vivo as an aid in the treatment of diabetes mellitus.
    Type: Grant
    Filed: October 4, 1991
    Date of Patent: June 21, 1994
    Assignee: Eli Lilly and Company
    Inventors: Douglas J. Allen, Kirk W. Johnson, Robert S. Nevin
  • Patent number: 5166063
    Abstract: The present invention provides a method for immobilizing biomolecules on a conductive substrate to produce a biosensor.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: November 24, 1992
    Assignee: Eli Lilly and Company
    Inventor: Kirk W. Johnson
  • Patent number: 5108819
    Abstract: A biocompatible thin film electrical component is configured for use in a human body or other ionic liquid environment. A polyimide substrate is bonded to a glass carrier plate sized for handling by automatic equipment and a multiple-layer metal conductor is deposited on the substrate and patterned to define an electrical circuit or biosensor. The polyimide and the glass establish a bond therebetween that withstands handling yet is know using biocompatible releasing agents and techniques. The polyimide substrate and glass carrier plate preferably have similar thermal expansion properties to reduce the likelihood of fracture and delamination problems during release of the substrate from the carrier plate. An insulation layer covers the metal conductor and, in one embodiment, is made of polyimide having a cure temperature lower than the temperature at which interediffusion occurrs in the metal layers in the conductor.
    Type: Grant
    Filed: February 14, 1990
    Date of Patent: April 28, 1992
    Assignee: Eli Lilly and Company
    Inventors: James W. Heller, David Lipson, Kirk W. Johnson